ArticleBMC nephrology2025
CTSS and CD53: Emerging m6A methylation markers in diabetic kidney disease pathogenesis and their clinical implications.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Emerging roles of mJournal of assisted reproduction and genetics · 2026Review
- The translational potential of m6A RNA methylation in DKD: emerging biomarkers for early detection and targeted therapies.Frontiers in medicine · 2026Review
- Immune-metabolic interactions shape the fibrotic landscape of diabetic kidney disease: emerging mechanisms and therapeutic prospects.Frontiers in physiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveDiabetic kidney disease (DKD) is increasingly recognized as a leading cause of chronic kidney disease (CKD) worldwide. Although N6-methyladenosine (m6A) mRNA modification is abundant in eukaryotes, its specific contribution to DKD pathogenesis is not well understood. This study aims to investigate the role of N6-methyladenosine (m6A) RNA modification patterns in DKD and their relationship with immune regulation.
methodsThree GEO datasets were analyzed to explore m6A modification patterns. Random forest modeling and consensus clustering were used for subtype identification. Immune cell infiltration was evaluated using ssGSEA. Key candidate genes were refined through LASSO regression and experimental verification in diabetic mouse models via qPCR.
resultsEight differentially expressed m6A regulators were identified in DKD. Two distinct m6A modification patterns were established, with cluster B showing enhanced immune cell infiltration. WTAP positively correlated with immune cell populations, while YTHDC2 showed negative correlations. CTSS and CD53 were identified as potential biomarkers and validated in diabetic mouse models, showing negative correlations with glomerular filtration rate.
conclusionsThis study reveals two m6A methylation patterns in DKD, with one associated with increased immune infiltration. We identified CTSS and CD53 as hub genes and validated them in diabetic mouse kidney tissues, suggesting their potential as clinical biomarkers for DKD. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.